Compositions and methods for treating autism
The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering α-methyl-DL-tyrosine.
1. A method for providing a plasma concentration of a therapeutic drug for a long term for treating an autism in a subject in need thereof, the method comprising administering to said subject said therapeutic drug at a concentration ranging from about 50 mg (w/w) to about 1500 mg (w/w) daily, wherein said therapeutic drug is α-methyl-DL-tyrosine, wherein said plasma concentration ranges from about 500 ng/ml to 5000 ng/ml, and wherein said term is at least 1 week.
2. The method of claim 1 , wherein the concentration of said therapeutic drug is about 90 mg (w/w/).
3. The method of claim 1 , wherein the concentration of said therapeutic drug is about 100 mg (w/w/).
4. The method of claim 1 , wherein the concentration of said therapeutic drug is about 200 mg (w/w/).
5. The method of claim 1 , wherein the concentration of said therapeutic drug is about 250 mg (w/w/).
6. The method of claim 1 , wherein the concentration of said therapeutic drug is about 300 mg (w/w/).
7. The method of claim 1 , wherein the concentration of said therapeutic drug is about 350 mg (w/w/).
8. The method of claim 1 , wherein said therapeutic drug is administered in a plurality of divided doses.
9. The method of claim 1 , wherein said therapeutic drug is administered for a duration ranging from about 1 week to about 4 weeks or more.
10. The method of claim 1 , wherein said plasma concentration ranges from about 800 ng/ml to 2500 ng/ml.
11. The method of claim 1 , wherein said plasma concentration ranges from about 1400 ng/ml to 1800 ng/ml.
12. A method for treating an autism associated clinical trait in a subject in need thereof, the method comprising administering to said subject a composition comprising a therapeutically effective amount of α-methyl-DL-tyrosine, thereby treating said autism associated clinical trait in said subject.
13. The method of claim 12 , wherein said clinical trait is a deficit in social communication, a deficit in social interaction, a deficit in social motivation, lethargy and social withdrawal, inappropriate speech, hyperactivity, stereotypic behavior, irritability and agitation, restrictive behavior, repetitive behavior, ritualistic behavior, sameness behavior, compulsive behavior, self-injurious behavior or a combination thereof.
14. The method of claim 12 , wherein said clinical trait meets the requirements of Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) criteria.
15. The method of claim 12 , wherein said clinical trait is assessed based upon a change from a baseline in one or more psychometric tests.
16. The method of claim 15 , wherein said psychometric test is based on clinical global impression (CGI) rating scale, Vineland adoptive behavior scale (VABS), autism diagnostic observation schedule (ADOS), social responsiveness scale (SRS), aberrant behavior checklist-community (ABC-C), repetitive behavior scale (RBS), Conners parent rating scale (CPRS), or a combination thereof.
17. The method of claim 12 , wherein the composition comprises α-methyl-DL-tyrosine in an amount ranging from about 50 mg (w/w) to about 1000 mg (w/w).
18. The method of claim 12 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 90 mg (w/w/).
19. The method of claim 12 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 100 mg (w/w/).
20. The method of claim 12 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 200 mg (w/w/).
21. The method of claim 12 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 250 mg (w/w/).
22. The method of claim 12 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 300 mg (w/w/).
23. The method of claim 12 , wherein the composition comprises α-methyl-DL-tyrosine in an amount of about 350 mg (w/w/).
24. The method of claim 12 , wherein the composition is administered in a plurality of divided doses.
25. The method of claim 12 , wherein the composition is administered three times per day.
26. The method of claim 12 , wherein the composition is administered for at least 1 week.
27. The method of claim 12 , wherein the composition is administered for a duration ranging from about 1 week to about 4 weeks.
28. A method for providing a plasma concentration of a therapeutic drug for a long term for treating an autism in a subject in need thereof, the method comprising administering to said subject said therapeutic drug at a concentration ranging from about 50 mg (w/w) to about 500 mg (w/w) daily, wherein said therapeutic drug is α-methyl-DL-tyrosine, wherein said plasma concentration ranges from about 500 ng/ml to 5000 ng/ml, and wherein said term is at least 1 week.